ChemAbout
© 2026 ChemAbout
İçgörüler|Gizlilik Politikası|Kullanım Koşulları|[email protected]
Ana Sayfa/Bileşikler/Aktif Farmasötik İngredient/Glucagon-like peptide 1 (1-37)
C186H275N51O59
4169 g/mol
Aktif Farmasötik İngredient

Glucagon-like peptide 1 (1-37)

CAS87805-34-3
Kategori
Aktif Farmasötik İngredient
Bileşik Sınıfı
Peptit
Birincil Kullanım
Farmasötik ham madde

Glucagon-like peptide 1 (1-37) is a 37-amino-acid peptide hormone derived from the proglucagon precursor. It is the initial product of posttranslational processing and serves as the precursor to the biologically active forms GLP-1 (7-36) amide and GLP-1 (7-37), which are produced in intestinal L-cells and brainstem neurons following food intake.

pharmaceutical raw material for manufacturing GLP-1 analogslaboratory reagent for peptide hormone researchcompound used in pharmaceutical development studies

İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.

Bu bileşiği tedarik ediyor veya sağlıyor musunuz?

Envanterinizi listeleyin veya satın alma talebi gönderin

CAS 87805-34-3

Bu Ürünü Listele
Tedarik bilgisi yayınlamak için oturum açın
Bu Ürünü Talep Et
Kayıt olmadan talep gönderin

İlgili Bileşikler

GüçlüBenzer yapıBenzerlik 0.96

GLP-1 (1-36) amide (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 trifluoroacetate salt

CAS99658-04-5

active pharmaceutical ingredient

GüçlüBenzer yapıBenzerlik 0.87

Liraglutide

CAS204656-20-2

anti-diabetic medication

GüçlüBenzer yapıBenzerlik 0.87

Semaglutide intermediate P29

CAS1169630-82-3

Semaglutide intermediate

GüçlüBenzer yapıBenzerlik 0.86

GLP-1 (7-37)

CAS106612-94-6

active pharmaceutical ingredient

ReferansAynı kategori

FORMOTEROL FUMARATE

CAS87833-61-2

beta-2 adrenergic receptor agonist

ReferansAynı kategori

Semprex

CAS87848-99-5

H1-receptor antagonist

ReferansAynı kategori

Ethyl (E)-3-(6-((E)-3-(pyrrolidin-1-yl)-1-(p-tolyl)prop-1-en-1-yl)pyridin-2-yl)acrylate

CAS87849-18-1

active pharmaceutical ingredient

ReferansAynı kategori

FOSTRIECIN SODIUM

CAS87860-39-7

active pharmaceutical ingredient

Tanımlayıcılar
IUPAC Adı

(4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid

InChIKey

UKVFVQPAANCXIL-FJVFSOETSA-N

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC8=CN=CN8)N

Eş Anlamlılar (5)
  • GLP-1 (1-37)
  • Glp-I (1-37)
  • Proglucagon (72-108)